The SHOC2 phosphatase complex as a therapeutic target for ERK pathway inhibition in RAS-driven tumors
Targeted inhibition of the ERK-MAPK pathway, upregulated in the majority of human cancers, has been hindered in the clinic by drug resistance and on-target toxicity. The MRAS-SHOC2-PP1 complex plays a key, but underexplored role in RAF-ERK pathway activation, by dephosphorylating a critical inhibito...
Main Author: | Jones, Greg Gordon |
---|---|
Published: |
University College London (University of London)
2018
|
Subjects: | |
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.763268 |
Similar Items
-
Discovery and optimisation of small-molecule ERK5 inhibitors as cancer therapeutics
by: Myers, Stephanie May
Published: (2013) -
Cellular responses to oncogenic Ras signalling
by: Mageean, Craig
Published: (2014) -
Isoform-specific Ras expression and signalling
by: Newlaczyl, A. U.
Published: (2016) -
Wild-type N-Ras complements mutant K-Ras in pancreatic cancer cell lines but K-Ras has a specific role in cell cycle independent regulation of G2 cyclins
by: Ferguson, Robert
Published: (2015) -
Role of VANGL1 as an effector of R-RAS
by: Hartig, N.
Published: (2013)